* Meta-terms correspond to biological or medical specialty concerned
with one or more keywords (or keywords hierarchies), qualifiers, or resource types.
Other terms also benefit from this structure, when the topic warrants it, eg education.
See the list.
Preferred Label : hematology;
True Meta (CISMeF) : O;
Origin ID : MT16;
UMLS CUI : C0018943;
ATC codes
Automatic exact mappings (from CISMeF team)
FMA entities
ICD-10 codes
ICD-11 codes
Indication(s)
MeSH
MeSH qualifiers
SNOMED CT concepts
SNOMED int. notions
See also
See also (suggested by CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://ansm.sante.fr/tableau-marr/sel-de-fer-injectable
2025
false
false
false
France
French
risk management
iron compounds
iron, parenteral preparations
patient education handout
guidelines for drug use
injections, intravenous
infusions, intravenous
iron compounds
anaphylaxis
drug hypersensitivity
Drug-Related side effects and adverse reactions
---
https://ansm.sante.fr/tableau-marr/pomalidomide
2025
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide
---
https://www.has-sante.fr/jcms/p_3574834/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
evaluation of the transparency committee
ivosidenib
ivosidenib
biliary tract, nos
neoplasm, malignant
Tibsovo
biliary tract neoplasms
biliary tract cancer
---
https://www.has-sante.fr/jcms/p_3576108/fr/adzynma-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc-pediatrie
2025
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Apadamtase Alfa
guidelines for drug use
apadamtase alfa and cinaxadamtase alfa
Cinaxadamtase Alfa
enzyme replacement therapy
ADAMTS13 protein, human
injections, intravenous
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
congenital thrombotic thrombocytopenic purpura
---
https://www.has-sante.fr/jcms/p_3576262/fr/jakavi-ruxolitinib-maladie-du-greffon-pediatrie
2025
false
false
false
France
administration, oral
pharmaceutical solutions
graft vs host disease
child
ruxolitinib
Janus Kinase Inhibitors
evaluation of the transparency committee
ruxolitinib
---
https://www.inserm.fr/actualite/plaquettes-sanguines-une-production-sous-pression/
2025
France
evaluation of the transparency committee
economics
pressure, nos
platelet
production
blood platelets
blood pressure
---
https://www.has-sante.fr/jcms/p_3586231/fr/adzynma-adamts13r-purpura-thrombotique-thrombocytopenique-congenital-pttc
2025
false
false
false
France
ADAMTS13 Protein
Apadamtase Alfa
enzyme replacement therapy
congenital thrombotic thrombocytopenic purpura
adult
child
treatment outcome
insurance, health, reimbursement
orphan drug production
injections, intravenous
Congenital thrombotic thrombocytopenic purpura
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
---
https://www.inspq.qc.ca/publications/3610
2025
Canada
technical report
quebec
organization and administration
Transfusion Reaction
---
https://www.has-sante.fr/jcms/p_3587094/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
Locally Advanced Cholangiocarcinoma
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
ivosidenib
adult
Metastatic Cholangiocarcinoma
IDH1 NP_005887.2:p.R132X
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
administration, oral
antineoplastic agents
evaluation of the transparency committee
ivosidenib
---
https://www.cancer.fr/catalogue-des-publications/securisation-medicamenteuse-des-patients-traites-par-anticancereux-injectables-en-hopital-de-jour-d-oncologie-hematologie-referentiel-organisatio
https://www.cancer.fr/catalogue-des-publications/securisation-medicamenteuse-des-patients-traites-par-anticancereux-injectables-en-hopital-de-jour-d-oncologie-hematologie-synthese
2025
false
false
false
France
guideline
drug therapy
hospitals
administration of therapeutic substance, nos
antineoplastic agents
hematology
patients
day care center
hospital, nos
has patient
hospitalization
injections
Oncologists
---
https://ansm.sante.fr/actualites/heparine-calcique-en-seringue-preremplie-tensions-dapprovisionnement-et-arret-de-commercialisation
2025
false
false
false
France
French
drug information
guideline
calcium heparin
injections, subcutaneous
Pre-filled Syringe
heparin
patients guideline
anticoagulants
---
https://www.cochrane.org/fr/CD013816/CENTRALED_la-poursuite-des-anticoagulants-chroniques-est-elle-preferable-leur-arret-proximite-ou-pendant
2025
United Kingdom
review of literature
french abstract
devices
anticoagulants
anticoagulant, nos
cardiac rhythm, nos
implant, nos
Set, Psychology
prostheses and implants
device, nos
heart rate
---
https://minerva-ebp.be/FR/Article/2423
2025
Belgium
critical appraisal or critical reading
cardiovascular risk
has patient
case histories
diabetes mellitus
systolic pressure
stroke/cerebrovascular accident
patients
Cardiovascular Risk
stroke
due to
cerebrovascular accident, nos
systolic arterial pulse pressure, nos
Embolic Stroke
risk
blood pressure, nos
blood pressure
---
https://ansm.sante.fr/tableau-marr/isatuximab
2025
false
false
false
France
French
risk management
isatuximab
guideline
patient education handout
blood transfusion
indirect coombs test
Laboratory test interference
---
https://www.cochrane.org/fr/CD013745/CENTRALED_quels-sont-les-benefices-et-risques-des-anticoagulants-oraux-directs-aod-les-anticoagulants-de
2025
United Kingdom
review of literature
french abstract
Transcatheter Aortic Valve Replacement
anticoagulant, nos
leadership
aortic valve
risk assessment
replacement of catheter
guideline
risks and benefits
generations
anticoagulants
aorta, nos
oral anticoagulants
family characteristics
---
https://www.cochrane.org/fr/CD016168/CENTRALED_quels-sont-les-benefices-et-risques-des-transfusions-de-sang-et-de-produits-sanguins-pour-la-prise
2025
United Kingdom
review of literature
french abstract
blood
risk assessment
blood transfusion
postpartum hemorrhage
risks and benefits
hemorrhage
transfusion, nos
postpartum hemorrhage, nos
blood specimen collection
patient care management
risk-taking
---
https://www.has-sante.fr/jcms/p_3597238/fr/calquence-acalabrutinib-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
Calquence
"u" lymphocyte
lymphoma, mantle-cell
acalabrutinib
acalabrutinib
malignant lymphoma, nos
---
https://ansm.sante.fr/tableau-marr/etranacogene-dezaparvovec
2025
false
false
false
France
French
risk management
Etranacogene Dezaparvovec
etranacogene dezaparvovec
guidelines for drug use
patients guideline
popular works
thromboembolism
Drug-Related side effects and adverse reactions
Chemical and Drug Induced Liver Injury
gene therapy
Gene Therapy Agents
semen
blood
DNA-Mediated Gene Transfer
pregnancy
gene transfer, horizontal
---
https://www.has-sante.fr/jcms/p_3599704/fr/ferrostrane-nourrissons-feredetate-de-sodium-carence-martiale
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
pharmaceutical solutions
administration, oral
sodium feredetate
evaluation of the transparency committee
Iron Deficiencies
ferric sodium edetate
infant
Fe(III)-EDTA
---
https://www.health.belgium.be/fr/criteres-dexclusion-temporaire-don-de-sang-evaluation-2024
2025
Belgium
technical report
evaluation studies as topic
blood donors
Blood Donation
transitory
---
https://www.cochrane.org/fr/CD011926/CENTRALED_les-tests-moleculaires-sont-ils-plus-efficaces-que-les-hemocultures-pour-detecter-les-infections
2025
United Kingdom
review of literature
french abstract
infectious disease, nos
blood
infant, newborn
Infections
Blood Culture
detective
blood culture, nos
newborn, nos
---
https://www.cochrane.org/fr/CD013835/CENTRALED_le-risque-de-deces-differe-t-il-entre-adultes-de-sexe-feminin-et-masculin-atteints-dembolie
2025
United Kingdom
review of literature
french abstract
pulmonary embolism
adulthood
safe sex
pulmonary embolism
female, nos
Male
risk
disease
sex
death
pulmonary embolism
unsafe sex
blood
female
lung
male, nos
adult
---
https://www.has-sante.fr/jcms/p_3542801/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique
2025
false
false
false
France
blinatumomab
antineoplastic agents
adult
treatment outcome
insurance, health, reimbursement
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Measurable Residual Disease Negativity
consolidation chemotherapy
evaluation of the transparency committee
precursor cell lymphoblastic Leukemia-Lymphoma
blinatumomab
---
https://ansm.sante.fr/tableau-marr/lisocabtagene-maraleucel
2025
false
false
false
France
French
guidelines for drug use
risk management
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal
product form)
Cytokine Release Syndrome
continuity of patient care
gene therapy
immunotherapy, adoptive
signs and symptoms
nervous system diseases
patients guideline
lisocabtagene maraleucel
---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2025
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
antineoplastic combined chemotherapy protocols
---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2025
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
graft vs host disease
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease
pharmaceutical solutions
child
guidelines for drug use
summary of product characteristics
package leaflet
tablets
---
https://www.has-sante.fr/jcms/p_3431851/fr/xenpozyme-olipudase-alfa-deficit-en-sphingomyelinase-acide
2025
false
false
false
France
evaluation of the transparency committee
sphingomyelin/cholesterol lipidosis, nos
xenpozyme
acid, nos
olipudase alfa
niemann-pick diseases
olipudase alfa
---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2025
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease
---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2025
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care
---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2025
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/xenpozyme#
2025
false
false
false
France
French
drug information
olipudase alfa
olipudase alfa
enzyme replacement therapy
child
adolescent
adult
niemann-pick diseases
---
https://ansm.sante.fr/tableau-marr/icodextrine
2025
false
false
false
France
French
risk management
guidelines for drug use
peritoneal dialysis
blood glucose self-monitoring
Icodextrin
Blood glucose meter (physical object)
directory
patient education handout
---
https://www.cochrane.org/fr/CD009752/CENTRALED_transfusions-sanguines-chez-les-personnes-nees-avec-des-problemes-cardiaques-qui-necessitent-une
2025
false
false
false
France
United Kingdom
review of literature
french abstract
heart defects, congenital
treatment outcome
child
infant, newborn
blood transfusion
blood transfusion
---
https://www.has-sante.fr/jcms/p_3575020/fr/tecartus-brexucabtagene-autoleucel-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
antigens, CD19
"u" lymphocyte
brexucabtagene autoleucel
brexucabtagene autoleucel
cells
---
https://hemato.chu-limoges.fr/
false
false
false
false
France
French
popular works
teaching structure
research structure
hematologic diseases
hematology
---
https://ansm.sante.fr/tableau-atu-rtu/kymriah-1-2-x-106-6-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
tisagenlecleucel
risk management
infusions, intravenous
antineoplastic agents
antineoplastic agents
patients guideline
---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19
---
https://ansm.sante.fr/tableau-marr/emicizumab
2024
false
false
false
France
French
emicizumab
risk management
thromboembolism
hemorrhage
thrombotic microangiopathies
blood coagulation tests
risk
hemorrhage
hemophilia A
patients guideline
guidelines for drug use
handbooks
Drug-Related side effects and adverse reactions
injections, subcutaneous
emicizumab
emicizumab
continuity of patient care
antibodies, bispecific
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide
---
https://ansm.sante.fr/tableau-marr/pembrolizumab
2024
false
false
false
France
French
risk management
pembrolizumab
Infusion related reaction
immune system diseases
Drug-Related side effects and adverse reactions
patient education handout
pregnancy
continuity of patient care
drug monitoring
Antineoplastic Agents, Immunological
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/tableau-marr/thalidomide
2024
false
false
false
France
French
risk management
thalidomide
teratogens
abnormalities, drug-induced
pregnancy
thalidomide
guideline
forms
patient education handout
continuity of patient care
Neuropathy peripheral
thromboembolism
Drug-Related side effects and adverse reactions
pregnancy tests
contraception
package leaflet
---
https://www.has-sante.fr/jcms/p_3534476/fr/brukinsa-zanubrutinib-lymphome-folliculaire-lf
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic agents
zanubrutinib
antineoplastic combined chemotherapy protocols
obinutuzumab
evaluation of the transparency committee
zanubrutinib
lymphoma, follicular
---
https://ansm.sante.fr/informations-de-securite/abecma-breyanzi-carvykti-kymriah-tecartus-et-yescarta-therapies-cellulaires-car-t-dirigees-contre-les-antigenes-cd19-ou-bcma-risque-de-tumeur-maligne-secondaire-issue-de-lymphocytes-t
2024
false
false
false
France
French
pharmacovigilance note
Secondary Malignant Neoplasm
Anti-CD19 CAR T Cells Preparation
Anti-BCMA CAR T Cells Preparation
Chimeric Antigen Receptor Therapy
lymphoma, T-Cell
continuity of patient care
hematologic neoplasms
leukemia, t-cell
Antineoplastic cell and gene therapy
---
https://www.has-sante.fr/jcms/p_3534500/fr/mentor
2024
France
health technology assessment
Smooth
Selective Estrogen Receptor Modulator
Round Cell Count
Sadness
Serum Sample
mentors
RWDD3 wt Allele
physiology
PHGDH wt Allele
breast implants
round shape
serum
serum
Round
Serum
Reversible Posterior Leukoencephalopathy Syndrome
physiologist
Breast Implant
breast, nos
implant, nos
Fill
---
https://www.has-sante.fr/jcms/p_3420797/fr/keytruda-pembrolizumab-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
breast neoplasms
pembrolizumab
breast cancer
pembrolizumab
Childhood Breast Carcinoma
Pembrolizumab
neoplasm, malignant
Male Breast Carcinoma
Keytruda
pembrolizumab
---
https://www.sggg.ch/fileadmin/user_upload/Dokumente/3_Fachinformationen/1_Expertenbriefe/Fr/EB_87_Stockage_de_cellules_souches_de_sang_de_cordon_ombilical_public.pdf
2024
Switzerland
guideline
Nano
Public
cord blood
MATCH Arm EAY131-N
No
Umbilical Cord Blood
N
stem cell
Stem Cell
fetal blood
stem cells
Neither Agree or Disagree
Murine Stem Cells
Newton
cord blood
Hoarding
Storage
expert testimony
expert opinion
N Category
Tumor to Normal
umbilical cord
Signal to Noise Ratio
blood cells
---
https://ansm.sante.fr/tableau-marr/iptacopan
2024
false
false
false
France
French
guidelines for drug use
risk management
patients guideline
Iptacopan
iptacopan
---
https://www.has-sante.fr/jcms/p_3537837/fr/fasenra-benralizumab-granulomatose-eosinophilique
2024
France
evaluation of the transparency committee
Eosinophilia
Granulomatosis
Benralizumab
eosinophils
benralizumab
eosinophilia, nos
eosinophilia
Fasenra
eosinophil
Eosinophilia, CTCAE
Eosinophil
Eosinophil Count
granulomatosis, nos
---
https://www.inspq.qc.ca/publications/3533
2024
Canada
technical report
portraits as topic
Infections
blood
projection
Portrait
quebec
Murine Blood
sexually transmitted diseases
Per Year
projection
Sexually Transmitted Disorder
infectious disease, nos
Blood Sample
Blood
---
https://www.has-sante.fr/jcms/p_3538225/fr/ayvakyt-avapritinib-mastocytose-systemique-indolente
2024
false
false
false
France
indolent systemic mastocytosis
treatment outcome
insurance, health, reimbursement
adult
administration, oral
avapritinib
evaluation of the transparency committee
mastocytosis, systemic
avapritinib
---
https://www.srlf.org/article/tazocilline-cefepime-reanimation-qui-fait-mieux
2024
France
critical appraisal or critical reading
Cefepime
Device Properties Domain
Reasoning
What Month is it
Dong Chinese
Resuscitation
Cefepime
Foundation for the Accreditation of Cellular Therapy
Doctor of Osteopathic Medicine
Better than Others
cefepime
resuscitation
Improved
Dominican Republic
---
https://www.has-sante.fr/jcms/p_3538933/fr/omjjara-momelotinib-splenomegalie-et-symptomes-lies-a-la-myelofibrose
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
momelotinib
anemia
adult
Secondary Myelofibrosis
administration, oral
Janus Kinase Inhibitors
evaluation of the transparency committee
primary myelofibrosis
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
splenomegaly
---
https://www.has-sante.fr/jcms/p_3538948/fr/siklos-hydroxycarbamide-drepanocytose
2024
false
false
false
France
evaluation of the transparency committee
hydroxyurea
hydroxyurea
hemoglobin s disease
anemia, sickle cell
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1388
2024
France
public health guidelines
west nile virus
paris
has assessment
dengue virus
Set, Psychology
evaluation studies as topic
device, nos
devices
simian immunodeficiency virus
french
play and playthings
france
blood
dengue virus, nos
bone screws
breast
---
https://www.has-sante.fr/jcms/p_3539105/fr/enbrel-etanercept-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
-
evaluation of the transparency committee
injections, subcutaneous
biological therapy
Etanercept
chronic disease
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1390
2024
France
public health guidelines
dengue
leadership
due to
organizations
registries
dengue
blood cells
snacks
adoption
blood donor, nos
population groups
tissues
organ part
bone screws
"u" lymphocyte
Indigenous Peoples
adoption, nos
simian immunodeficiency virus
cells
blood donors
---
https://ansm.sante.fr/actualites/vitamine-b12-injectable-et-buvable-preferez-les-comprimes-aux-ampoules-pour-lusage-par-voie-orale
2024
false
false
false
France
French
drug information
guideline
injections, intramuscular
administration, oral
vitamin B 12
Malabsorption of Vitamin B12
vitamin b 12 deficiency
cyanocobalamin
-
-
---
https://www.youtube.com/watch?v=z-YsqT_3OKE
2024
France
audiovisual aids
blood specimen collection
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/dosage-sanguin-du-titane-par-spectrometrie-de-masse-a-plasma-a-couplage-inductif-icp-ms.html
2024
Canada
health technology assessment
plasma
mass spectrometry
blood volume, nos
titanium
plasma
lung clearance index
titanium measurement
percutaneous coronary intervention
---
https://ansm.sante.fr/tableau-acces-derogatoire/blincyto
2024
false
false
false
France
French
insurance, health, reimbursement
blinatumomab
Consolidation Therapy
guidelines for drug use
summary of product characteristics
package leaflet
blinatumomab
infusions, intravenous
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
precursor b-cell lymphoblastic leukemia-lymphoma
Measurable Residual Disease Negativity
---
https://www.has-sante.fr/jcms/p_3546684/fr/keytruda-pembrolizumab-carcinome-urothelial
2024
false
false
false
France
urologic neoplasms
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
enfortumab vedotin
adult
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
pembrolizumab
evaluation of the transparency committee
carcinoma
pembrolizumab
---
https://ansm.sante.fr/informations-de-securite/oxbryta-voxelotor-suspension-de-lautorisation-de-mise-sur-le-marche-de-lunion-europeenne
https://ansm.sante.fr/actualites/oxbryta-voxelotor-conduite-a-tenir-suite-a-la-suspension-de-lautorisation-de-mise-sur-le-marche
2024
false
false
false
France
French
Safety-Based drug withdrawals
voxelotor
pharmacovigilance note
voxelotor
guidelines for drug use
drugs, investigational
france
europe
hematologic agents
Vaso-Occlusive Crisis
---
https://www.has-sante.fr/jcms/p_3546934/fr/keytruda-pembrolizumab-cancer-du-rein-en-adjuvant
2024
false
false
false
France
Clear Cell Renal Cell Carcinoma
carcinoma, renal cell
treatment outcome
insurance, health, reimbursement
adult
Antineoplastic Agents, Immunological
pembrolizumab
Adjuvant Therapy
nephrectomy
risk
recurrence
evaluation of the transparency committee
pembrolizumab
---
https://ansm.sante.fr/tableau-marr/eculizumab-1
2024
false
false
false
France
French
risk management
guidelines for drug use
eculizumab
eculizumab
continuity of patient care
Drug-Related side effects and adverse reactions
vaccination
patients guideline
Infections
sepsis
meningococcal infections
risk
---
https://ansm.sante.fr/tableau-marr/eculizumab-2
2024
false
false
false
France
French
risk management
eculizumab
eculizumab
eculizumab
guidelines for drug use
patient education handout
patients guideline
antibiotic prophylaxis
infusions, intravenous
Infections
sepsis
Drug-Related side effects and adverse reactions
meningococcal infections
vaccination
meningococcal vaccines
---
https://ansm.sante.fr/actualites/fibrinogene-humain-lansm-a-elabore-un-guide-pratique-pour-favoriser-le-bon-usage-des-produits-disponibles
2024
false
false
false
France
French
drug compounding
drug storage
guidelines for drug use
fibrinogen
human fibrinogen
Fibrinogen Human
Product containing only human fibrinogen (medicinal product)
fibrinogen
---
https://ansm.sante.fr/actualites/hemovigilance-lansm-fait-evoluer-la-declaration-des-effets-indesirables-donneurs-de-sang
2024
false
false
false
France
French
scientific and technical information
blood safety
hemovigilance
blood donors
reports of adverse events
france
---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib
---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab
---
https://ansm.sante.fr/tableau-marr/elranatamab
2024
false
false
false
France
French
risk management
Elranatamab
drug information
patients guideline
Cytokine Release Syndrome
nervous system diseases
elranatamab
---
https://www.has-sante.fr/jcms/p_3488284/fr/caspofungine-tillomed-caspofungine-antimycotique-a-usage-systemique
2024
false
false
false
France
drugs, generic
infusions, intravenous
caspofungin
evaluation of the transparency committee
Caspofungin
antifungal agents
---
https://www.has-sante.fr/jcms/p_3488174/fr/nplate-romiplostim-thrombopenie-immunologique-primaire-pti-refractaire-aux-autres-traitements
2024
false
false
false
France
Primary Immune Thrombocytopenia
evaluation of the transparency committee
nplate
principal
Romiplostim
Immunotherapy
romiplostim
Refractory
thrombocytopenia due to immune destruction, nos
Primary Refractory
romiplostim
idiopathic thrombocytopenic purpura, nos
Other Therapy
Immune
Immunology
thrombocytopenia
purpura, thrombocytopenic, idiopathic
immunology
---
https://ansm.sante.fr/tableau-marr/susoctocog-alfa
2024
false
false
false
France
French
risk management
Susoctocog Alfa
medication errors
guidelines for drug use
drug dosage calculations
video recording
---
https://www.has-sante.fr/jcms/p_3490841/fr/reblozyl-luspatercept-anemie-associee-a-une-beta-thalassemie
2024
false
false
false
France
evaluation of the transparency committee
beta-Thalassemia
luspatercept
---
https://ansm.sante.fr/tableau-marr/mecasermine
2024
false
false
false
France
French
risk management
mecasermin
mecasermin
mecasermin
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
mecasermin
hypoglycemia
injections, subcutaneous
---
https://www.canada.ca/fr/sante-publique/services/maladies-infectieuses/sante-sexuelle-infections-transmissibles-sexuellement/lignes-directrices-canadiennes/guide-prevention-itss.html
2024
Canada
guideline
public health guidelines
Blood Sample
Prevention Study
Guide Device
infectious disease, nos
Prevention
Murine Blood
Sexually Transmitted Disorder
Preventive Intervention
Handbook
Blood
infection control
blood
sexually transmitted diseases
---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib
---
https://www.has-sante.fr/jcms/p_3497026/fr/mircera-methoxy-polyethylene-glycol-epoetine-beta-anemie-symptomatique-associee-a-l-insuffisance-renale-chronique-chez-les-enfants-ages-de-3-mois-a-moins-de-18-ans
2024
false
false
false
France
infant
adolescent
treatment outcome
insurance, health, reimbursement
hematinics
methoxy polyethylene glycol-epoetin beta
Anemia of chronic renal failure (disorder)
evaluation of the transparency committee
continuous erythropoietin receptor activator
polyethylene glycols
anemia
erythropoietin
methoxy polyethylene glycol-epoetin beta
renal insufficiency, chronic
child
---
https://www.cochrane.org/fr/CD011858/RENAL_traitements-pour-fluidifier-le-sang-pendant-lhemodialyse-quels-sont-les-traitements-qui-reduisent
2024
United Kingdom
review of literature
french abstract
Issue
Hemorrhage
blood
problem, nos
Blood Sample
evoked
Dexamethasone
hemodialysis
Coagulation Process
hemorrhage, nos
hemodialysis, nos
hemorrhage
coagulants
renal dialysis
Hemodialysis
Blood
coagulant, nos
Murine Blood
Biggest Problem
What Month is it
Adverse Event Associated with Coagulation
---
https://www.has-sante.fr/jcms/p_3498568/fr/lovenox-enoxaparine-sodique-traitement-antithrombotique
2024
false
false
false
France
evaluation of the transparency committee
enoxaparin
antithrombotic agents
Treat
During Treatment
No Treatment for Diabetes
Therapy Object
fibrinolytic agents
Treatment Epoch
Treatment
Biomaterial Treatment
On Treatment
Thrombolytic Agent
GDC Treatment Frequency Terminology
Treatment Study
Enoxaparin Sodium
lovenox
---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/protocole-medical-national-initier-un-test-immunochimique-de-recherche-de-sang-occulte-dans-les-selles-ou-une-coloscopie-a-des-fins-de-depistage-ou-de-diagnostic-du-cancer-colorectal.html
2024
Canada
public health guidelines
Test Name
immunochemistry
colonoscopy
On Study
screening for cancer
dermatomyositis
Colorectal Cancer
Cancer Diagnosis
biomedical research
Laboratory Procedure
Screening Colonoscopy
Test Dosing Unit
Screening for Colorectal Cancer
cancer screening
malignant neoplasm colon/rectum
early detection of cancer
Initiation
diagnosis
no diagnosis
Fecal Occult Blood Test
Blood Products Laboratory Testing
feces
screening for occult blood in feces
Clinical Study Protocol
medical research
colorectal neoplasms
occult blood
---
https://www.has-sante.fr/jcms/p_3500938/fr/ultravist-iopromide-produit-de-contraste-iode
2024
false
false
false
France
evaluation of the transparency committee
iopromide
iodine
contrast media
---
https://minerva-ebp.be/FR/Analysis/855
2024
Belgium
critical appraisal or critical reading
pulmonary embolism
guideline
anticoagulants
anticoagulotherapy
leadership
Anticoagulation Therapy
Update
anticoagulant, nos
Pulmonary Embolism
Direct Oral Anticoagulant
pulmonary embolism
Long-Term
pulmonary embolism
oral anticoagulants
Software Maintenance
---
https://www.has-sante.fr/jcms/p_3501630/fr/tepkinly-epcoritamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
epcoritamab
injections, subcutaneous
Antineoplastic Agents, Immunological
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
Third-Line Therapy
evaluation of the transparency committee
lymphoma, large B-Cell, diffuse
Epcoritamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy
---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following
nephrectomy and resection of metastatic lesions
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma
---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2024
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel
---
https://ansm.sante.fr/tableau-marr/rituximab-3
2024
false
false
false
France
French
guidelines for drug use
patient education handout
Rituximab
Rituximab
risk management
continuity of patient care
child
infusions, intravenous
leukoencephalopathy, progressive multifocal
Drug-Related side effects and adverse reactions
---
https://ansm.sante.fr/tableau-marr/ravulizumab
2024
false
false
false
France
French
risk management
ravulizumab
ravulizumab
ravulizumab
infusions, intravenous
guidelines for drug use
patients guideline
continuity of patient care
meningococcal infections
sepsis
neisseria meningitidis
vaccination
antibiotic prophylaxis
meningococcal infections
sepsis
child
infant
hemoglobinuria, paroxysmal
Atypical Hemolytic Uremic Syndrome
myasthenia gravis, generalized
---
https://ansm.sante.fr/tableau-acces-derogatoire/oxbryta-voxelotor
2024
false
false
false
France
French
risk management
voxelotor
voxelotor
administration, oral
hematologic agents
drug information
anemia, hemolytic
anemia, sickle cell
Safety-Based drug withdrawals
---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2024
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive
---
https://ansm.sante.fr/tableau-acces-derogatoire/breyanzi
2024
false
false
false
France
French
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal
product form)
summary of product characteristics
package leaflet
guidelines for drug use
lymphoma, large B-Cell, diffuse
adult
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
continuity of patient care
immunotherapy, adoptive
antigens, CD19
lisocabtagene maraleucel
---
https://ansm.sante.fr/tableau-marr/teclistamab
2024
false
false
false
France
French
popular works
drug information
Teclistamab
risk management
teclistamab
---
https://ansm.sante.fr/tableau-marr/olipudase-alfa
2024
false
false
false
France
French
guidelines for drug use
popular works
risk management
olipudase alfa
olipudase alfa
Drug-Related side effects and adverse reactions
infusions, intravenous
home infusion therapy
Infusion-Related Reaction
drug hypersensitivity
anaphylaxis
olipudase alfa
---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2024
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy
---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2024
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel
---
https://ansm.sante.fr/tableau-marr/panobinostat
2024
false
false
false
France
French
risk management
Panobinostat
panobinostat
administration, oral
medication errors
patients guideline
patient compliance
---
https://ansm.sante.fr/tableau-marr/eculizumab
2024
false
false
false
France
French
risk management
guidelines for drug use
eculizumab
eculizumab
continuity of patient care
drug monitoring
patient safety
sepsis
meningococcal infections
risk
vaccination
antibiotic prophylaxis
adult
child
infant
patients guideline
patient education handout
Drug-Related side effects and adverse reactions
meningococcal vaccines
---
https://ansm.sante.fr/tableau-atu-rtu/mylotarg-5-mg-poudre-pour-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
Gemtuzumab
gemtuzumab ozogamicin
guidelines for drug use
continuity of patient care
drug monitoring
leukemia, myeloid, acute
adult
child
recurrence
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
CD33 Positive
antineoplastic combined chemotherapy protocols
infusions, intravenous
Antineoplastic Agents, Immunological
gemtuzumab ozogamicin
technical report
---
https://ansm.sante.fr/tableau-marr/romiplostim
2024
false
false
false
France
French
injections, subcutaneous
romiplostim
risk management
romiplostim
guidelines for drug use
child
adult
patients guideline
clinical tool
home nursing
drug dosage calculations
self administration
receptors, fc
recombinant fusion proteins
thrombopoietin
---
https://www.cochrane.org/fr/CD004736/CENTRALED_effets-dune-supplementation-quotidienne-en-fer-par-voie-orale-pendant-la-grossesse
2024
false
false
false
United Kingdom
France
dietary supplements
anemia, iron-deficiency
neural tube defects
treatment outcome
pregnancy complications, hematologic
meta-analysis
french abstract
folic acid
administration, oral
iron
pregnancy
---
https://www.ema.europa.eu/medicines/human/EPAR/Metalyse
2024
false
United Kingdom
French
English
syndication feed
Acute cerebrovascular accident due to ischemia (disorder)
Ischemic Stroke
myocardial infarction
thrombolytic therapy
tissue plasminogen activator
tissue plasminogen activator
tissue plasminogen activator
tissue plasminogen activator
fibrinolytic agents
fibrinolytic agents
fibrinolytic agents
fibrinolytic agents
treatment outcome
drug evaluation
injections, intravenous
tenecteplase
tissue plasminogen activator
drug evaluation
summary of product characteristics
package leaflet
tissue plasminogen activator
Tenecteplase
Tenecteplase
---
https://www.cochrane.org/fr/CD010189/CENTRALED_cellules-souches-de-la-moelle-osseuse-ou-cellules-souches-du-sang-peripherique-quelle-est-la
2024
false
false
false
France
United Kingdom
French
meta-analysis
french abstract
hematologic neoplasms
treatment outcome
bone marrow transplantation
peripheral blood stem cell transplantation
recurrence
hematologic neoplasms
comparative study
---
http://publications.msss.gouv.qc.ca/msss/document-000179/
2024
false
false
false
false
Canada
French
scientific and technical information
resulting in
genes
physicians
hemoglobinopathies
carrier state, nos
hemoglobinopathy, nos
Handbook
interpreter
Handbook
---
https://www.has-sante.fr/jcms/p_3546280/fr/ultravist-iopromide-produit-de-contraste-iode
2024
false
false
false
France
iopromide
neoplasm staging
Tumor Size Measurement
breast neoplasms
evaluation of the transparency committee
iopromide
contrast media
---
https://minerva-ebp.be/FR/Article/2398
2024
Belgium
critical appraisal or critical reading
elderly person, nos
atrial fibrillation
frail elderly
leadership
anticoagulant, nos
vitamine K antagonist
antivitamins K
guideline
anticoagulants
persistent
antivitamins K
oral anticoagulants
atrial fibrillation
---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/heparine-choay-25-000-ui-5-ml-solution-injectable-1-flacon-s-en-verre-de-5-ml-heparine-sodique
2024
false
false
false
France
French
drug information
heparin
Sodium Heparin
heparin
---
https://www.has-sante.fr/jcms/p_3554633/fr/sarclisa-isatuximab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Bortezomib/Dexamethasone/Isatuximab/Lenalidomide Regimen
adult
infusions, intravenous
Antineoplastic Agents, Immunological
isatuximab
evaluation of the transparency committee
multiple myeloma
isatuximab
---
https://www.has-sante.fr/jcms/p_3554842/fr/tecvayli-teclistamab-myelome-multiple
2024
false
false
false
France
Teclistamab
teclistamab
treatment outcome
insurance, health, reimbursement
multiple myeloma
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
antibodies, bispecific
evaluation of the transparency committee
---
https://ansm.sante.fr/tableau-acces-derogatoire/sarclisa
2024
false
false
false
France
French
drug information
infusions, intravenous
isatuximab
antineoplastic combined chemotherapy protocols
multiple myeloma
Bortezomib/Dexamethasone/Isatuximab/Lenalidomide Regimen
---
https://ansm.sante.fr/actualites/decision-du-08-11-2024-portant-abrogation-du-cpc-des-medicaments-velcade-1-mg-et-3-5mg-poudre-pour-solution-injectable-et-des-medicaments-du-meme-groupe-generique
2024
false
false
false
France
French
drug information
legislation, pharmacy
Bortezomib
Immunoglobulin Light-chain Amyloidosis
---
https://www.has-sante.fr/jcms/p_3560833/fr/aspaveli-pegcetacoplan-hemoglobinurie-paroxystique-nocturne-hpn
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
pegcetacoplan
infusions, subcutaneous
adult
anemia, hemolytic
evaluation of the transparency committee
pegcetacoplan
hemoglobinuria, paroxysmal
paroxysmal nocturnal hemoglobinuria
---
https://www.has-sante.fr/jcms/p_3560827/fr/fabhalta-iptacopan-hemoglobinurie-paroxystique-nocturne-hpn
2024
false
false
false
France
Iptacopan Hydrochloride
treatment outcome
insurance, health, reimbursement
adult
anemia, hemolytic
iptacopan
administration, oral
evaluation of the transparency committee
hemoglobinuria, paroxysmal
paroxysmal nocturnal hemoglobinuria
---
https://www.has-sante.fr/jcms/p_3560836/fr/voydeya-danicopan-hemoglobinurie-paroxystique-nocturne-hpn
2024
false
false
false
France
drug therapy, combination
adult
treatment outcome
insurance, health, reimbursement
complement inactivating agents
anemia, hemolytic
ravulizumab
eculizumab
danicopan
administration, oral
evaluation of the transparency committee
paroxysmal nocturnal hemoglobinuria
danicopan
hemoglobinuria, paroxysmal
---
https://ansm.sante.fr/tableau-marr/adamts13r
2024
false
false
false
France
French
risk management
ADAMTS13 Protein
guidelines for drug use
drug hypersensitivity
drug hypersensitivity
signs and symptoms
patient education handout
enzyme replacement therapy
adult
child
congenital thrombotic thrombocytopenic purpura
ADAMTS13 Protein
recombinant proteins
---
https://www.ema.europa.eu/en/medicines/human/EPAR/adzynma
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
child
adult
congenital thrombotic thrombocytopenic purpura
enzyme replacement therapy
ADAMTS13 protein, human
recombinant proteins
ADAMTS13 Protein
ADAMTS13 Protein
risk management
pregnancy
breast feeding
drug approval
europe
injections, intravenous
von willebrand factor
product surveillance, postmarketing
aged
apadamtase alfa and cinaxadamtase alfa
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1406
2024
France
public health guidelines
Contraindications
judgment
Blood Donation
risk
blood donors
object relations
object attachment
patient selection
selection criteria
contraindication to
---
https://www.santepubliquefrance.fr/regions/provence-alpes-cote-d-azur-et-corse/documents/enquetes-etudes/2024/observatoire-des-cancers-du-rein-de-la-vessie-et-des-leucemies-aigues-chez-l-adulte-dans-le-departement-des-bouches-du-rhone-revela13-.-analyses
2024
France
technical report
leukaemia
leukemia
kidney
mouth
spatial analysis
adult
urinary bladder
adulthood
---
https://www.cbip.be/fr/articles/4461?folia=4453
2024
false
false
false
Belgium
French
pharmacovigilance note
journal article
Selective Serotonin Reuptake Inhibitors
anticoagulants
drug interactions
administration, oral
antivitamins K
Direct Oral Anticoagulant
---
https://www.chu-lyon.fr/etp-mon-tca-les-autres-et-moi
2024
France
patient education handout
ego
partial thromboplastin time
coagulation time, activated
Feeding and Eating Disorders
---
https://www.chu-lyon.fr/leucemie-aigue
2024
France
patient education handout
leukemia
leukaemia
---
https://www.chu-lyon.fr/traitement-de-lanemie-par-carence-en-fer
2024
France
patient education handout
iron deficiency
iron deficiency anemia, nos
anemia, iron-deficiency
---
https://www.cochrane.org/fr/CD014541/CENTRALED_une-strategie-danticoagulants-de-longue-duree-pour-prevenir-le-developpement-de-caillots-sanguins
2024
United Kingdom
review of literature
french abstract
duration
hospital, nos
blood clot, nos
anticoagulant, nos
hospitals
lung
anticoagulants
acute disease, nos
resulting in
acute disease
has patient
attentiveness
patients
---
https://www.sfmu.org/upload/consensus/RFE2024_Anticoagulation_contexte_urgence.pdf
2024
France
guideline
health planning guidelines
anticoagulant, nos
emergencies
anticoagulants
---
https://www.sfmu.org/upload/consensus/RPP2024_prevention_antithrombotique_urgence.pdf
2024
France
guideline
health planning guidelines
fibrinolytic agents
antithrombotic agents
emergencies
---
https://www.chu-lyon.fr/hemoglobinurie-paroxystique-nocturne-hpn
2024
France
popular works
hemoglobinuria, paroxysmal
paroxysmal nocturnal hemoglobinuria
paroxysmal nocturnal hemoglobinuria
hydrocephalus, normal pressure
---
https://www.cochrane.org/fr/CD010861/CENTRALED_quels-sont-les-effets-du-traitement-pour-les-femmes-atteintes-danemie-ferriprive-apres-laccouchement
2024
United Kingdom
review of literature
french abstract
disease
parturition, nos
anemia, iron-deficiency
anemia
parturition
women
iron deficiency anemia, nos
---
https://www.cochrane.org/fr/CD016120/CENTRALED_quels-sont-les-benefices-et-les-risques-de-lutilisation-de-la-recuperation-du-sang-pendant-la
2024
United Kingdom
review of literature
french abstract
risks and benefits
blood
parturition
risk assessment
birth, nos
---
https://www.chu-lyon.fr/aplasie-medullaire
2024
France
popular works
anemia, aplastic
hypoplasia of bone marrow
---
https://www.chu-lyon.fr/etp-des-patients-hemophiles-ou-risque-hemorragique-ou-b-severes-ou-moderes
2024
France
popular works
severe
education
patient care planning
has patient
therapeutics
hemorrhage, nos
hemophilia b, nos
hemorrhage
hemophilia B
temperance
Program
risk
patient education as topic
patients
---
https://www.cochrane.org/fr/CD013293/RENAL_quelle-est-la-meilleure-methode-pour-sauver-un-acces-dhemodialyse-coagule
2024
United Kingdom
review of literature
french abstract
coagulant, nos
Hemodialysis
Test Method
protestantism
coagulants
hemodialysis
What Month is it
CDISC SDTM Method Terminology
Clotted Specimen
Methodology
renal dialysis
hemodialysis, nos
Technique
Dexamethasone
---
https://www.has-sante.fr/jcms/p_3503249/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antibodies, monoclonal
adult
multiple myeloma
package leaflet
summary of product characteristics
guidelines for drug use
recurrence
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Progressive Neoplastic Disease
relapsed and refractory multiple myeloma, who have received at least three prior therapies,
including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
and have demonstrated disease progression on the last therapy
elranatamab
evaluation of the transparency committee
Elranatamab
---
https://sfar.org/gestion-de-lanticoagulation-dans-un-contexte-durgence/
2024
France
guideline
algorithms
anticoagulants
Application Context
emergencies
anticoagulant, nos
Anticoagulant Agent
Contingency Management
---
https://sfar.org/optimisation-hemodynamique-perioperatoire-adulte-dont-obstetrique/
2024
France
guideline
Optimization
obstetrics
hemodynamics
Perioperative
Observational Study Sampling Method
---
https://sfar.org/optimisation-hemodynamique-perioperatoire-pediatrie/
2024
France
guideline
Perioperative
pediatrics
hemodynamics
Pediatric
pediatrician
Optimization
Pediatric
---
https://www.cochrane.org/fr/CD014544/CF_quels-sont-les-benefices-et-les-risques-des-nouveaux-traitements-par-facteurs-non-coagulants-pour-la
2024
United Kingdom
review of literature
french abstract
risk factors
blood coagulation factors
hemophilia B
bloodletting
coagulants
Treatment Benefit
Feeding
Breeding
Risk Factor
Coagulation Factor
hemophilia b, nos
persons
risks and benefits
risk factor
F9 wt Allele
Feeding Ability
Prevention Study
Hemophilia B
What Month is it
disease
Raw
coagulation factor, nos
Hemorrhage
Preventive Intervention
risk assessment
bleeding precautions
hemorrhage
People
New Lesion Identification
Newar Language
preventive treatment, nos
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab
---
https://ansm.sante.fr/tableau-marr/sutimlimab
2024
false
false
false
France
French
risk management
sutimlimab
guidelines for drug use
sutimlimab
antibodies, monoclonal, humanized
infusions, intravenous
Infections
Infections
meningococcal vaccines
meningococcal infections
vaccination
serious infection
patient education handout
---
https://ansm.sante.fr/tableau-acces-derogatoire/blenrep
2024
false
false
false
France
French
infusions, intravenous
drug information
antibodies, monoclonal, humanized
belantamab mafodotin
Antineoplastic Agents, Immunological
---
https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
drug approval
Elranatamab
Elranatamab
multiple myeloma
recurrence
Progressive Neoplastic Disease
Triple-Class Refractory Multiple Myeloma
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Recurrent Multiple Myeloma
antibodies, monoclonal
antibodies, monoclonal
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
injections, subcutaneous
bispecific monoclonal antibodies
bispecific monoclonal antibodies
Immune Effector Cell Associated Neurotoxicity Syndrome
Elranatamab
Cytokine Release Syndrome
continuity of patient care
relapsed and refractory multiple myeloma, who have received at least three prior therapies,
including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
and have demonstrated disease progression on the last therapy
elranatamab
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/equivalence-du-seuil-de-positivite-des-tests-immunochimiques-de-recherche-de-sang-occulte-dans-les-selles-pour-le-depistage-du-cancer-colorectal.html
2024
Canada
review of literature
feces
early detection of cancer
Equivalent
screening for occult blood in feces
cancer screening
screening for cancer
Research
Search
research
immunochemistry
Blood in Stool
colorectal neoplasms
Occult Blood Measurement
Colorectal Cancer
Screening for Colorectal Cancer
occult blood
Liquid Tumor
malignant neoplasm colon/rectum
---
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child
---
https://www.has-sante.fr/jcms/p_3517015/fr/fabhalta-iptacopan-hemoglobinurie-paroxystique-nocturne
2024
false
false
false
France
iptacopan
treatment outcome
insurance, health, reimbursement
paroxysmal nocturnal hemoglobinuria
hemoglobinuria, paroxysmal
adult
guidelines for drug use
administration, oral
complement inactivating agents
orphan drug production
anemia, hemolytic
Iptacopan Hydrochloride
evaluation of the transparency committee
Iptacopan
---
https://www.has-sante.fr/jcms/p_3518105/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique-lal-chez-l-adulte
2024
false
false
false
France
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
insurance, health, reimbursement
treatment outcome
antineoplastic agents
blinatumomab
infusions, intravenous
Precursor B-cell acute lymphoblastic leukemia
evaluation of the transparency committee
adult
blinatumomab
---
https://www.has-sante.fr/jcms/p_3517560/fr/soliris-eculizumab-myasthenie
2024
false
false
false
France
eculizumab
generalised myasthenia gravis with anti-acetylcholine receptor antibody
treatment outcome
child
Acetylcholine receptor antibody (substance)
infusions, intravenous
evaluation of the transparency committee
eculizumab
myasthenia gravis
---
https://www.has-sante.fr/jcms/p_3517411/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
relapsed and refractory multiple myeloma, who have received at least three prior therapies,
including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
and have demonstrated disease progression on the last therapy
Recurrent Multiple Myeloma
antibodies, monoclonal
Triple-Class Refractory Multiple Myeloma
adult
injections, subcutaneous
Progressive Neoplastic Disease
recurrence
elranatamab
evaluation of the transparency committee
multiple myeloma
Elranatamab
---
https://pap-pediatrie.fr/nephro-uro/purpura-rhumatoide-chez-lenfant
2024
France
scientific and technical information
algorithms
child
Child Relation
IgA Vasculitis
child, nos
Child Individual
purpura rheumatica
rheumatoid purpura
Henoch-Schönlein Purpura
---
https://www.rheuma-net.ch/fr/doc/cyclophosphamid-1/viewdocument/348
2024
Switzerland
guideline
cyclophosphamide
cyclophosphamide
Background Treatment
Cyclophosphamide
---
https://ansm.sante.fr/tableau-acces-derogatoire/fabhalta
2024
false
false
false
France
French
Iptacopan
iptacopan
summary of product characteristics
package leaflet
guidelines for drug use
paroxysmal nocturnal hemoglobinuria
adult
anemia, hemolytic
complement factor B
C3 Glomerulonephritis
---
https://www.ema.europa.eu/en/medicines/human/EPAR/voydeya
2024
false
false
false
Netherlands
French
English
drug approval
europe
danicopan
danicopan
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
adult
paroxysmal nocturnal hemoglobinuria
administration, oral
complement factor D
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
danicopan
drug evaluation, preclinical
---
https://www.cochrane.org/fr/CD013590/CF_les-supplements-dantioxydants-aident-ils-les-personnes-atteintes-de-drepanocytose-globules-rouges-de
2024
false
false
false
United Kingdom
review of literature
french abstract
What Month is it
Murine Erythrocytes
abnormal red cell, nos
Erythrocyte
antioxidants
Abnormal Reference Range
erythrocytes, abnormal
disease
abnormal shape, nos
Sickle Cell Disease
Vaping
People
persons
anemia, sickle cell
Percent of Abnormal Cells
hemoglobin s disease
---
https://www.has-sante.fr/jcms/p_3431997/fr/tibsovo-ivosidenib-servier-ivosidenib-leucemie-aigue-myeloide
2024
false
false
false
France
evaluation of the transparency committee
Tibsovo
ivosidenib
ivosidenib
Ivosidenib
---
https://www.has-sante.fr/jcms/p_3522395/fr/vanflyta-quizartinib-leucemie-aigue-myeloide-lam
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
quizartinib
antineoplastic combined chemotherapy protocols
cytarabine
anthracyclines
adult
FLT3 Internal Tandem Duplication
Acute Myeloid Leukemia with FLT3/ITD Mutation
evaluation of the transparency committee
leukemia, myeloid, acute
quizartinib
---
https://www.has-sante.fr/jcms/p_3527465/fr/ultomiris-ravulizumab-inhibiteur-du-complement-c5
2024
false
false
false
France
insurance, health, reimbursement
infusions, intravenous
ravulizumab
evaluation of the transparency committee
complement inactivating agents
complement inactivator proteins
complement C5
ravulizumab
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/utilisation-judicieuse-des-hemocultures.html
2024
Canada
guideline
Use
Blood Culture
blood culture, nos
---
https://www.has-sante.fr/jcms/p_3528746/fr/flash-securite-patient-gestion-perioperatoire-des-anticoagulants-patients-aidants-soignants-coagulez-vous
2024
France
popular works
Management Occupations
Nursing Assistants
anticoagulants
Management
Veterinary Patient
patients
Safety Study
CASP8AP2 wt Allele
Patient
has patient
Anticoagulant Agent
Perioperative
has provider
Safety
safety management
nurses' aides
anticoagulant, nos
Adverse Event Associated with Coagulation
Coagulation Process
Clotted Specimen
patient safety
coagulants
coagulant, nos
---
https://minerva-ebp.be/FR/Article/2383
2024
Belgium
critical appraisal or critical reading
oral anticoagulants
guideline
Deep Vein Thrombosis
deep vein thrombosis
Anticoagulation Therapy
anticoagulotherapy
deep thrombophlebitis, nos
Direct Oral Anticoagulant
venous thrombosis
leadership
anticoagulants
anticoagulant, nos
---
https://www.has-sante.fr/jcms/p_3530407/fr/cyclophosphamide-accord-cyclophosphamide-cancer-et-maladies-auto-immunes
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing only cyclophosphamide in parenteral dose form (medicinal product
form)
precursor cell lymphoblastic Leukemia-Lymphoma
cyclophosphamide
transplantation conditioning
multiple myeloma
hodgkin disease
lymphoma, Non-Hodgkin
ovarian neoplasms
breast neoplasms
neoplasm metastasis
sarcoma, ewing
small cell lung carcinoma
bronchial neoplasms
neuroblastoma
lupus nephritis
Granulomatosis with Polyangiitis
myeloablative agonists
antineoplastic agents, alkylating
immunosuppressive agents
evaluation of the transparency committee
cyclophosphamide
autoimmune diseases
---
https://www.ce-mir.fr/files/medias/documents/17-ch08-085-100-9782294769580.pdf
2024
France
educational course
Blood Transfusion
transfusion, nos
blood transfusion
---
https://www.ce-mir.fr/files/medias/documents/35.%20Gaz%20du%20sang%20et%20troubles%20de%20l%27%C3%A9quilibre%20acidobasique.pdf
2024
France
educational course
blood
gas, nos
PAGR1 wt Allele
Hematopoietic and Lymphoid Cell Disorder
blood gas analysis
pH Homeostasis
GAST wt Allele
gases
disorder of balance, nos
acid-base imbalance
---
https://www.ce-mir.fr/files/medias/documents/36.%20%C3%89tiologie%20des%20anomalies%20gazom%C3%A9triques%20d%27origine%20m%C3%A9tabolique.pdf
2024
France
educational course
Abnormality
Molecular Genetic Variation
blood gas analysis
Metabolic Process
Abnormal Indicator
Metabolic
defect, nos
CDISC Define-XML Origin Source Terminology
metabolism
general metabolic function, nos
---
https://www.ce-mir.fr/files/medias/documents/47.%20Purpura%20fulminans.pdf
2024
France
educational course
purpura fulminans
Purpura, CTCAE
Purpura
purpura fulminans
---
https://www.ce-mir.fr/files/medias/documents/62.%20Accidents%20h%C3%A9morragiques%20des%20anticoagulants.pdf
2024
France
educational course
Anticoagulant Agent
anticoagulants
Hemorrhage
Occurrence
hemorrhage
anticoagulant, nos
hemorrhage, nos
accident, nos
accidents
---
https://www.ce-mir.fr/files/medias/documents/63.%20Thrombop%C3%A9nie%20en%20soins%20critiques.pdf
2024
France
educational course
thrombocytopenia, nos
critical care
Care
nursing
thrombocytopenia
Healthcare
Healthcare Activity
How True Feel Carefree Right Now
---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/hematologie-cancerologie/anemie-pathologies-du-fer
2024
France
educational course
anemia, nos
Iron
iron, nos
disease
Anemia
Diseased
anemia
FER Gene
Dietary Iron
Iron Measurement
iron
Pathology
---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/hematologie-cancerologie/adenopathies-superficielles
2024
France
educational course
Lymphadenopathy
enlargement of lymph nodes, nos
Lymphadenopathy
Lymphadenopathy
---
https://www.cochrane.org/fr/CD013366/PVD_quels-sont-les-benefices-et-les-risques-des-innovations-concernant-les-materiaux-et-la-conception
2024
United Kingdom
review of literature
french abstract
infectious disease, nos
risk assessment
lifting
Reprint Carrier
risks and benefits
Genetic Carrier
GDC Therapeutic Agent Terminology
Plastic
blood
Tube Dosing Unit
CDISC SEND Study Design Terminology
plastics
complication, nos
veins
Catheterization
Transportation
conception
conception
Infections
Infection
Pharmacologic Substance
carrying
transportation
Transport Device
drug, nos
Design
pharmaceutical preparations
Transfer
catheters
Blood
Carrying
Carrier Device
Blood Sample
fertilization
Complication
Conception
Medication
Conception Age
Murine Blood
equipment safety
Transport Process
plastic tube
Delivery
---
https://www.hgr-css.be/fr/avis/9763/lutilisation-eclairee-du-sang-o-negatif
2024
Belgium
public health guidelines
CDH1 Gene Mutation Negative
Wnt Negative
KIT Negative
Oxygen
Osmium
Use
Negative Lymph Node
Unmethylated MGMT Gene Promoter
GNA11 Gene Mutation Negative
Blood Sample
Epstein-Barr Virus Negative
Hepatitis B Virus Surface Antigen Negative
umeclidinium
BAP1 Gene Mutation Negative
TERT Promoter Mutation Negative
lightning
KRAS Gene Mutation Negative
Negative Number
ATRX Gene Mutation Negative
ERBB2 Gene Amplification Negative
ERBB2 Gene Mutation Negative
Blood Group O
FGFR2 Gene Mutation Negative
Blood
PAX8 Gene Rearrangement Negative
Hepatitis B Surface Antibody Negative
Hepatitis B Virus Core Antibody Negative
blood
ESR2 Negative
FGFR2 Gene Rearrangement Negative
Progesterone Receptor Negative
IDH Family Wildtype
Human Immunodeficiency Virus Negative
Lack of Expression of PD-L1
NRAS Gene Mutation Negative
ERG Gene Rearrangement Negative
FGFR3 Gene Mutation Negative
RET Gene Rearrangement Negative
Murine Blood
GNAQ Gene Mutation Negative
FGFR3 Gene Rearrangement Negative
10q23/PTEN Locus Deletion Negative
ANO1 Negative
CDKN2A-p16 Negative
SDHA Negative
lighting
CTNNB1 Gene Mutation Negative
SDHB Negative
Beryllium
Be
HRAS Gene Mutation Negative
PAS Negative
Negative Charge
BRAF Gene Mutation Negative
FGFR1 Gene Mutation Negative
ETV Gene Rearrangement Negative
lightning
---
https://www.has-sante.fr/jcms/p_3427490/fr/nexpovio-selinexor-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
administration, oral
selinexor
antineoplastic agents
antineoplastic combined chemotherapy protocols
adult
Dexamethasone/Selinexor Regimen
Triple-Class Refractory Multiple Myeloma
evaluation of the transparency committee
selinexor
multiple myeloma
---
https://www.has-sante.fr/jcms/p_3428384/fr/xalkori-crizotinib-lymphome-t-anaplasique-a-grandes-cellules-lagc-pediatrie
2023
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
antineoplastic agents
crizotinib
guidelines for drug use
administration, oral
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
recurrence
protein kinase inhibitors
evaluation of the transparency committee
lymphoma, large-cell, anaplastic
Crizotinib
---
https://www.has-sante.fr/jcms/p_3427913/fr/soliris-eculizumab-syndrome-hemolytique-et-uremique-atypique-shua
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
eculizumab
infusions, intravenous
adult
child
evaluation of the transparency committee
Atypical Hemolytic Uremic Syndrome
eculizumab
---
https://www.has-sante.fr/jcms/p_3433395/fr/nexpovio-selinexor-myelome-multiple
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
multiple myeloma
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
administration, oral
selinexor
selinexor
antineoplastic combined chemotherapy protocols
dexamethasone
Dexamethasone/Selinexor Regimen
Refractory Multiple Myeloma
adult
antineoplastic agents
drug resistance, neoplasm
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/pertinence-dajouter-les-variantes-hbs-e-hbe-e-et-hbe-b-thal-aux-cibles-primaires-du-test-de-depistage-neonatal-des-hemoglobinopathies.html
2023
Canada
public health guidelines
hemoglobinopathy, nos
hemoglobinopathies
principal
neonatal screening, nos
Hemoglobinopathy
neonatal screening
dermatomyositis
---
https://www.has-sante.fr/jcms/p_3433398/fr/ultomiris-ravulizumab-syndrome-hemolytique-et-uremique-atypique-shua
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
ravulizumab
complement C5
complement inactivating agents
evaluation of the transparency committee
ravulizumab
Atypical Hemolytic Uremic Syndrome
---
https://www.has-sante.fr/jcms/p_3434604/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique
2023
false
false
false
France
evaluation of the transparency committee
zanubrutinib
leukemia, lymphoid
leukaemia
zanubrutinib
Brukinsa
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
chronic lymphocytic leukemia
---
https://www.has-sante.fr/jcms/p_3434163/fr/lonquex-lipegfilgrastim-facteur-de-croissance-granulocytaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
lipegfilgrastim
adult
child
adolescent
Chemotherapy-Induced febrile neutropenia
Chemotherapy-Induced febrile neutropenia
evaluation of the transparency committee
granulocyte colony-stimulating factor
lipegfilgrastim
---
http://nuxeo.edel.univ-poitiers.fr/nuxeo/site/esupversions/dda32ff9-7ea7-43de-9b76-dfa1836a68e4
2023
France
Physicians
activir
aged
case management
disease
has patient
patient care
role
activator appliances
principal
physician's role
medicine
physicians
hematology
primary health care
physicians, primary care
antineoplastic agents
Hematology
---
https://www.has-sante.fr/jcms/p_3442461/fr/xalkori-crizotinib-tumeurs-myofibroblastiques-inflammatoires-tmi
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Crizotinib
crizotinib
Inflammatory Myofibroblastic Tumor
antineoplastic agents
protein kinase inhibitors
child
adolescent
Childhood Inflammatory Myofibroblastic Tumor
soft tissue neoplasms
ALK Positive
administration, oral
---
https://pap-pediatrie.fr/immuno-infectio-parasito/splenomegalie-chez-lenfant
2023
France
algorithms
Child
splenomegaly, nos
child
Splenomegaly
Child
Child
splenomegaly
splenomegaly
Child
child, nos
---
https://minerva-ebp.be/FR/Article/2323
2023
Belgium
critical appraisal or critical reading
aspirin
anticoagulant, nos
cardiovascular prevention
principal
role
primary prevention
anticoagulants
systolic pressure
acetylsalicylic acid
---
https://www.has-sante.fr/jcms/p_3444027/fr/hemgenix-etranacogene-dezaparvovec-hemophilie-b
2023
false
false
false
France
adult
treatment outcome
Etranacogene Dezaparvovec
genetic therapy
hemophilia B
etranacogene dezaparvovec
evaluation of the transparency committee
hemophilia B
---
https://www.has-sante.fr/jcms/p_3443949/fr/hemlibra-emicizumab-hemophilie-a
2023
false
false
false
France
emicizumab
treatment outcome
insurance, health, reimbursement
hemorrhage
guidelines for drug use
evaluation of the transparency committee
hemophilia A
emicizumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
sutimlimab
sutimlimab
sutimlimab
orphan drug production
cold agglutinin disease
anemia, hemolytic, autoimmune
adult
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Etranacogene Dezaparvovec
Etranacogene Dezaparvovec
etranacogene dezaparvovec
gene therapy
orphan drug production
adult
hemophilia B
hemorrhage
infusions, intravenous
factor IX
F9 Gene
product surveillance, postmarketing
drug interactions
pregnancy
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/epysqli
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
eculizumab
eculizumab
eculizumab
biosimilar pharmaceuticals
hemoglobinuria, paroxysmal
adult
child
pregnancy
breast feeding
drug interactions
product surveillance, postmarketing
infusions, intravenous
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ivosidenib
ivosidenib
ivosidenib
orphan drug production
antineoplastic agents
antineoplastic agents
adult
enzyme inhibitors
enzyme inhibitors
antineoplastic combined chemotherapy protocols
Azacitidine/Ivosidenib Regimen
leukemia, myeloid, acute
IDH1 NP_005887.2:p.R132X
leukemia, myeloid, acute
IDH1 Gene Mutation
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
mutation
administration, oral
IDH1 protein, human
IDH1 inhibitor
product surveillance, postmarketing
drug interactions
fertility
pregnancy
breast feeding
drug evaluation, preclinical
acute myeloid leukaemia with an IDH1 R132 mutation
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
---
https://www.has-sante.fr/jcms/p_3444785/fr/xalkori-crizotinib-lymphome-anaplasique-a-grandes-cellules-lagc
2023
false
false
false
France
French
treatment outcome
child
insurance, health, reimbursement
administration, oral
Crizotinib
crizotinib
evaluation of the transparency committee
adolescent
Refractory Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
antineoplastic agents
protein kinase inhibitors
lymphoma, large-cell, anaplastic
---
https://ansm.sante.fr/informations-de-securite/adakveo-crizanlizumab-retrait-de-lautorisation-de-mise-sur-le-marche-en-raison-dun-manque-defficacite
2023
false
false
false
France
French
drug information
Drug effect lack of
crizanlizumab
crizanlizumab
anemia, sickle cell
Vaso-Occlusive Crisis
Safety-Based drug withdrawals
---
https://www.has-sante.fr/jcms/p_3448025/fr/oxbryta-voxelotor-anemie-hemolytique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
voxelotor
hematologic agents
anemia, sickle cell
adult
adolescent
summary of product characteristics
drug therapy, combination
evaluation of the transparency committee
voxelotor
anemia, hemolytic
---
https://www.has-sante.fr/jcms/p_3396878/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2023
false
false
false
France
triple negative breast neoplasms
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
pembrolizumab
antineoplastic combined chemotherapy protocols
infusions, intravenous
Locally Advanced Triple-Negative Breast Carcinoma
Early Stage Triple-Negative Breast Carcinoma
locally advanced triple negative breast cancer at high risk of recurrence
early stage triple negative breast cancer at high risk of recurrence
evaluation of the transparency committee
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3409403/fr/keytruda-pembrolizumab-carcinome-a-cellule-renale
2023
false
false
false
France
chemotherapy, adjuvant
treatment outcome
insurance, health, reimbursement
pembrolizumab
infusions, intravenous
Antineoplastic Agents, Immunological
clear cell renal cell carcinoma
nephrectomy
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following
nephrectomy and resection of metastatic lesions
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://www.has-sante.fr/jcms/p_3445722/fr/gabarit-mammaire-gonflable
2023
France
health technology assessment
anatomists
breast, nos
serum
with texture
serum
physiologist
Anatomy
anatomy
anatomist
Anatomy
physiology
microscopy
---
https://www.has-sante.fr/jcms/p_3445728/fr/gabarit-mammaire-gonflable
2023
France
health technology assessment
microscopy
serum
anatomist
breast, nos
anatomists
Anatomy
physiologist
serum
Anatomy
with texture
anatomy
physiology
---
https://www.has-sante.fr/jcms/p_3447489/fr/ebvallo-tabelecleucel-hemopathie-maligne
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Tabelecleucel
Adoptive Cell Therapy Agent
adult
child
adolescent
EBV-Related Post-Transplant Lymphoproliferative Disorder
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
tabelecleucel
evaluation of the transparency committee
Malignant hemopathy
hematologic neoplasms
---
https://ansm.sante.fr/tableau-acces-derogatoire/ebvallo
2023
false
false
false
France
French
drug information
Tabelecleucel
---
https://www.has-sante.fr/jcms/p_3447364/fr/hemlibra-emicizumab-hemophilie-a-deficit-congenital-en-facteur-viii
2023
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
emicizumab
hemophilia A
hemorrhage
emicizumab
evaluation of the transparency committee
---
http://oncologik.fr/referentiels/sforl/adenopathies-metastatiques-de-carcinome-epidermoide-sans-porte-d-entree
2023
France
guideline
Squamous cell carcinoma
enlargement of lymph nodes, nos
carcinoma, squamous cell
Lymphadenopathy
Adenopathy
squamous cell carcinoma, metastatic, nos
entrance
---
https://creaiors-occitanie.fr/wp-content/uploads/2023/06/CREAI-ORS_synthese-EPS-PA-2022_FIN_20230525.pdf
2023
France
scientific and technical information
elderly person, nos
exophthalmos producing substance
equipment
health
health education
health facility size
aged, 80 and over
aged
blood protein electrophoresis
gatekeeping
---
https://cps.ca/fr/documents/position/la-prise-en-charge-de-la-neutropenie-febrile-chez-les-enfants-et-les-adolescents-immunocompetents
2023
Canada
practice guideline
patient care management
Adolescent
increased body temperature
child
febrile neutropenia
Child
Child
adolescent
neutropenia, nos
Neutropenia
Adolescent
Child
child, nos
Child
adolescence
---